Keyphrases
Aortic Stenosis
100%
New-onset Atrial Fibrillation
88%
Cardiovascular Mortality
82%
Simvastatin
80%
Ezetimibe
78%
Atrial Fibrillation
73%
Cardiovascular Events
68%
Myocardial Infarction
68%
All-cause Mortality
57%
Statins
57%
Left Ventricular Hypertrophy
53%
Hypertensive Patients
50%
Confidence Interval
46%
Losartan
42%
Severe Aortic Stenosis
42%
Statin Therapy
39%
Low Risk
35%
Hazard Ratio
30%
Preventive Effect
28%
Aortic Valve Replacement
28%
Heart Rate
27%
Lipid-lowering
27%
Soluble Urokinase Plasminogen Activator Receptor (suPAR)
25%
End-diastolic Volume
25%
New Biomarkers
25%
Sudden Cardiac Death
25%
Systematic Meta-analysis
25%
Renin-angiotensin System Inhibitors
25%
Psoriasis
25%
Resting Heart Rate
25%
Renin-angiotensin System
25%
Life Studies
25%
Non-associated
25%
Persistent Atrial Fibrillation
25%
Eccentric Hypertrophy
25%
Cataract
25%
Group Classification
25%
Adverse Cardiovascular Events
25%
Dilatation
25%
Meta-analysis
25%
LV Mass
20%
Reinfarction
18%
Non-fatal
18%
Nonfatal Stroke
18%
Coronary Artery Bypass Grafting
17%
Multivariable
15%
Propensity Score Analysis
15%
Cardiovascular Disease
15%
Inflammation
15%
Major Adverse Cardiovascular Events
15%
Medicine and Dentistry
Aortic Stenosis
100%
Cardiovascular System
83%
Ezetimibe
78%
Simvastatin
78%
Left Ventricular Hypertrophy
55%
Apoplexy
52%
Losartan
50%
All Cause Mortality
42%
Cardiovascular Mortality
42%
Atrial Fibrillation
35%
Myocardial Infarction
27%
Cardiovascular Disease
27%
End-Diastolic Volume
25%
Biological Marker
25%
Psoriasis
25%
Urokinase Receptor
25%
Renin Angiotensin Aldosterone System
25%
Resting Heart Rate
25%
Cataract
25%
Sudden Cardiac Death
25%
Proportional Hazards Model
24%
Atenolol
22%
Hazard Ratio
20%
Aortic Valve Replacement
18%
C Reactive Protein
15%
Pharmacology, Toxicology and Pharmaceutical Science
Heart Infarction
78%
Atrial Fibrillation
77%
New-Onset Atrial Fibrillation
68%
All Cause Mortality
63%
Heart Left Ventricle Hypertrophy
55%
Statin (Protein)
54%
Losartan
51%
Aortic Stenosis
50%
Cerebrovascular Accident
46%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
44%
Cardiovascular Mortality
36%
Simvastatin
30%
Ezetimibe
28%
Angiotensin
25%
Sudden Cardiac Death
25%
Cataract
25%
Psoriasis
25%
Infarction
25%
Renin
25%
Atenolol
23%